Seeking regulatory approval for Foundayo in Europe, the company is facing market headwinds as Foundayo revenue misses analyst estimates reported by FactSet.

1 report, 1 independent Updated Aug 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Eli Lilly and Company Europe FactSet

Keep exploring

Part of

Financial analysis and consensus estimates detail the competitive GLP-1 market between Eli Lilly and Novo Nordisk. All 3 developments

Within Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.

The entities involved

Eli Lilly and Company
American pharmaceutical company
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
- The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
Europe
terrestrial continent located in north-western Eurasia
- The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
FactSet
American financial data company
- FactSet estimates suggest S&P 500 growth potential, while simultaneously, Fed rate hikes introduce risks of a market drawdown.Mon 09:50
- FactSet released its peg for the P/E ratio of the S&P 500 index.Mon 09:50

Related events

Eli Lilly's Foundayo is undergoing global market rollout, including a launch in the UK, ongoing review in the EU, and utilization in the US.Sep 5

Coverage

Newest first; wire copies grouped

Aug 11cnbc.com